Get the Stockscreener App
12.02
0.08%
0.010
After Hours:
12.11
0.09
+0.75%
Elanco Animal Health Inc stock is traded at $12.02, with a volume of 3.39M.
It is up +0.08% in the last 24 hours and down -2.36% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
See More
Previous Close:
$12.01
Open:
$12.02
24h Volume:
3.39M
Relative Volume:
0.77
Market Cap:
$5.94B
Revenue:
$4.45B
Net Income/Loss:
$205.00M
P/E Ratio:
30.05
EPS:
0.4
Net Cash Flow:
$372.00M
1W Performance:
+5.16%
1M Performance:
-2.36%
6M Performance:
-7.89%
1Y Performance:
-18.78%
1-Day Range:
$11.97
$12.19
1-Week Range:
$11.17
$12.19
52-Week Range:
$11.11
$18.80
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
2500 INNOVATION WAY, GREENFIELD
Compare ELAN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
12.02 | 5.94B | 4.45B | 205.00M | 372.00M | 0.40 |
|
ZTS
Zoetis Inc
|
165.89 | 74.84B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
12.92 | 40.96B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.92 | 24.83B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
143.26 | 14.50B | 2.24B | 385.90M | 440.10M | 3.73 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
2025-01-19 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Investors to Learn More About the Investigation | NYSE:ELAN | Press Release - Stockhouse Publishing
ELAN (Elanco Animal Health) Deferred Tax : $0 Mil (TTM As of Sep. 2024) - GuruFocus.com
US FDA approves Elanco's treatment for parasitic infections in dogs - AOL
Elanco Animal Health's SWOT analysis: stock outlook amid product challenges - MSN
ELAN (Elanco Animal Health) Long-Term Debt : $4,313 Mil (As of Sep. 2024) - GuruFocus.com
Elanco Animal Health’s SWOT analysis: stock outlook amid product challenges - Investing.com Nigeria
Companion Animal Ear Infection Treatment Market SWOT Analysis by Leading Expert: Elanco, Vetoquinol, Ceva - openPR
2025-01-15 | Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NYSE:ELAN | Press Release - Stockhouse Publishing
Veterinary Vaccines Market SWOT Analysis by Leading Expert: Virbac, Elanco, HIPRA - openPR
ELAN (Elanco Animal Health) Change In Working Capital : $239 Mil (TTM As of Sep. 2024) - GuruFocus.com
2025-01-12 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Connect | NYSE:ELAN | Press Release - Stockhouse Publishing
Is Elanco Animal Health (ELAN) the Best Medical Stock to Buy Under $20? - Insider Monkey
12 Best Medical Stocks To Buy Under $20 - Insider Monkey
Elanco Animal Health Incorporated (NYSE:ELAN) Stock Position Increased by Harbor Capital Advisors Inc. - MarketBeat
Elanco Animal Health (FRA:5EA) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Jan. 10, 2025) - GuruFocus.com
Elanco Animal Health (FRA:5EA) Gross Profit : €2,236 Mil (TTM As of Sep. 2024) - GuruFocus.com
Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Recommendation of “Hold” from Analysts - Defense World
Animal Health Business Research Report 2024-2030 Featuring Major PlayersBayer, Boehringer Ingelheim, Ceva Sante Animale, Elanco, Heska, Merck, Nutreco, Vetiquinol, Virbac, and Zoetis - Yahoo Finance
17,250 Shares in Elanco Animal Health Incorporated (NYSE:ELAN) Purchased by Everence Capital Management Inc. - Defense World
Elanco Animal Health (NYSE:ELAN) Reaches New 52-Week Low on Analyst Downgrade - Defense World
Elanco Animal Health (FRA:5EA) Other Long Term Assets : €272 Mil (As of Sep. 2024) - GuruFocus.com
Douglas Lane & Associates LLC Trims Position in Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Growth Trends in the Porcine Vaccines Market, Forecast to 2028: Increasing Government Initiatives for Funding Animal Husbandry - GlobeNewswire Inc.
Elanco Animal Health (NYSE:ELAN) Sets New 1-Year Low on Analyst Downgrade - MarketBeat
2025-01-08 | Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Stockholders to Inquire about Securities Investigation | NYSE:ELAN | Press Release - Stockhouse Publishing
Elanco Animal Health (NYSE:ELAN) Takes On Some Risk With Its Use Of Debt - Simply Wall St
Versant Capital Management Inc Sells 1,241 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - Defense World
Stifel Nicolaus Lowers Elanco Animal Health (NYSE:ELAN) Price Target to $18.00 - MarketBeat
Veterinary Oncology Market Generated Opportunities, Future - openPR
Principal Financial Group Inc. Sells 21,919 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - Defense World
2025-01-05 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Investors to Learn More About the Investigation | NYSE:ELAN | Press Release - Stockhouse Publishing
JPMorgan Chase & Co. Increases Position in Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Animal Hormones Market Forecast: Size, Share, Growth, Key - openPR
Elanco Animal Health (NYSE:ELAN) investors are sitting on a loss of 60% if they invested five years ago - Yahoo Finance
Franklin Resources Inc. Acquires 45,795 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.12%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):